Advanced in Squamous Cell Skin Carcinoma

Dr. Gino In

Oncology
USC Norris Comprehensive Cancer Center And Hospital
1441 Eastlake Ave, 
Los Angeles, CA 
Offers Telehealth
Advanced in Squamous Cell Skin Carcinoma
USC Norris Comprehensive Cancer Center And Hospital
1441 Eastlake Ave, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gino In is an Oncologist in Los Angeles, California. Dr. In is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Melanoma, Eccrine Porocarcinoma, Merkel Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Squamous Cell Skin Carcinoma.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Los Angeles General Medical Center
Keck Hospital Of USC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

USC Norris Comprehensive Cancer Center and Hospital
1441 Eastlake Ave, Los Angeles, CA 90089
Call: 323-865-3105

Additional Areas of Focus

Dr. In has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Biological, Procedure
Study Drug: Cemiplimab
Study Phase: Phase 2
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2025
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study
Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 10 Less Clinical Trials

63 Total Publications

Multiple Primary Acral Lentiginous Melanomas With BRCA1 Mutation.
Multiple Primary Acral Lentiginous Melanomas With BRCA1 Mutation.
Journal: JAAD case reports
Published: October 13, 2025
View All 63 Publications
Similar Doctors
Advanced in Squamous Cell Skin Carcinoma
Dr. Jacob S. Thomas
Oncology | Hematology Oncology
Advanced in Squamous Cell Skin Carcinoma
Dr. Jacob S. Thomas
Oncology | Hematology Oncology

USC Care Medical Group Inc

1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
 (0.2 miles away)
323-442-2582
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacob Thomas is an Oncologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Thomas is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Squamous Cell Skin Carcinoma, Nasopharyngeal Carcinoma, Ewing Sarcoma, and Bone Tumor.

Advanced in Squamous Cell Skin Carcinoma
Dr. Rupali K. Nabar
Oncology | Hematology
Advanced in Squamous Cell Skin Carcinoma
Dr. Rupali K. Nabar
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rupali Nabar is an Oncologist and a Hematologist in Orange, California. Dr. Nabar is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Laryngeal Cancer, Squamous Cell Skin Carcinoma, Bone Tumor, and Teratocarcinosarcoma.

Advanced in Squamous Cell Skin Carcinoma
Dr. Kevin S. Scher
Hematology Oncology | Hematology | Oncology
Advanced in Squamous Cell Skin Carcinoma
Dr. Kevin S. Scher
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Care Foundation

200 N Robertson Blvd, Suite 202, 
Beverly Hills, CA 
 (10.4 miles away)
310-423-3078
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Scher is a Hematologist Oncology specialist and a Hematologist in Beverly Hills, California. Dr. Scher is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Colorectal Cancer, Muscle Invasive Bladder Cancer, and Urothelial Cancer.

VIEW MORE SQUAMOUS CELL SKIN CARCINOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. In's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. In is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Distinguished
  • Eccrine Porocarcinoma
    Dr. In is
    Distinguished
    . Learn about Eccrine Porocarcinoma.
    See more Eccrine Porocarcinoma experts
  • Merkel Cell Carcinoma
    Dr. In is
    Distinguished
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
  • Advanced
  • Adult Soft Tissue Sarcoma
    Dr. In is
    Advanced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. In is
    Advanced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Basal Cell Skin Cancer
    Dr. In is
    Advanced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
  • Bone Tumor
    Dr. In is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chromophobe Renal Cell Carcinoma
    Dr. In is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. In is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
View All 23 Advanced Conditions
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. In is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. In is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. In is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anal Cancer
    Dr. In is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angioimmunoblastic T-cell Lymphoma
    Dr. In is
    Experienced
    . Learn about Angioimmunoblastic T-cell Lymphoma.
    See more Angioimmunoblastic T-cell Lymphoma experts
  • Angiosarcoma
    Dr. In is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
View All 55 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.